Screener
Enliven Therapeutics ELVN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $20,687 | $24,895 |
| General and administrative | 7,136 | 6,798 |
| Total operating expenses | 27,823 | 31,693 |
| Loss from operations | (27,823) | (31,693) |
| Other income (expense), net | ||
| Interest income | 4,196 | 3,196 |
| Other expense | — | (47) |
| Total other income (expense), net | 4,196 | 3,149 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's operating income?
- Enliven Therapeutics (ELVN) reported operating income of -$27.82M in Q1 2026.
- How has Enliven Therapeutics's operating income changed year-over-year?
- Enliven Therapeutics's operating income increased by 12.2% year-over-year, from -$31.69M to -$27.82M.
- What is the long-term trend for Enliven Therapeutics's operating income?
- Over 4 years (2021 to 2025), Enliven Therapeutics's operating income has grown at a 23.5% compound annual growth rate (CAGR), from -$51.44M to -$119.66M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Enliven Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude